Compare LPTH & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPTH | DRTS |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2011 | 2021 |
| Metric | LPTH | DRTS |
|---|---|---|
| Price | $13.12 | $14.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $13.33 | $8.67 |
| AVG Volume (30 Days) | ★ 2.6M | 492.6K |
| Earning Date | 05-14-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $37,202,630.00 | N/A |
| Revenue This Year | $83.04 | N/A |
| Revenue Next Year | $24.83 | $699.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.26 | N/A |
| 52 Week Low | $4.71 | $3.18 |
| 52 Week High | $18.94 | $15.02 |
| Indicator | LPTH | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 54.29 | 64.70 |
| Support Level | $9.85 | $6.47 |
| Resistance Level | $16.06 | N/A |
| Average True Range (ATR) | 1.03 | 0.59 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 52.60 | 90.62 |
LightPath Technologies Inc manufactures, distributes, and integrates proprietary optical components and assemblies. It develops optical solutions for traditional optics and communications markets. The company's products include precision molded optics and infrared products, serving markets such as distribution, laser, industrial, instrumentation, telecommunications, and defense. Its products are categorized as infrared components, visible components, assemblies and modules, and engineering services. G5 Infrared's revenue mainly comes from infrared components and assemblies.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.